

Financial Statements of

**BRITISH COLUMBIA
LUNG ASSOCIATION**

Year ended March 31, 2018



KPMG LLP
Metro Tower I
4710 Kingsway, Suite 2400
Burnaby BC V5H 4M2
Canada
Telephone (604) 527-3600
Fax (604) 527-3636

INDEPENDENT AUDITORS' REPORT

To the Members of the British Columbia Lung Association

Report on the Financial Statements

We have audited the accompanying financial statements of British Columbia Lung Association, which comprise the statement of financial position as at March 31, 2018, the statements of operations, changes in net assets and cash flows for the year then ended, notes, and schedules, comprising a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Canadian generally accepted auditing standards. Those standards require that we comply with ethical requirements and plan and perform an audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.



We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified audit opinion.

Basis of Qualified Opinion

In common with many charitable organizations, British Columbia Lung Association derives revenue from donations, the completeness of which is not susceptible to satisfactory audit verification. Accordingly, our verification of these revenues was limited to the amounts recorded in the records of British Columbia Lung Association. Therefore, we were not able to determine whether, as at or for the years ended March 31, 2018 and 2017, any adjustments might be necessary to donations revenues and excess of revenues over expenses reported in the statement of operations, excess of revenues over expenses in the statement of cash flows and current assets and unrestricted net assets recorded in the statement of financial position. This caused us to qualify our audit opinion on the financial statements as at and for the year ended March 31, 2017.

Qualified Opinion

In our opinion, except for the possible effects of the matter described in the Basis of Qualified Opinion paragraph, the financial statements present fairly, in all material respects, the financial position of British Columbia Lung Association as at March 31, 2018, and its results of operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

Report on Other Legal and Regulatory Requirements

As required by the Societies Act (British Columbia), we report that, in our opinion, the accounting policies applied in preparing and presenting the financial statements in accordance with Canadian accounting standards for not-for-profit organizations have been applied on a basis consistent with that of the preceding year.

A handwritten signature in black ink that reads 'KPMG LLP'. The signature is written in a cursive, slightly slanted style. Below the signature is a horizontal line that starts under the 'K' and ends under the 'P', with a small upward tick at the end.

Chartered Professional Accountants

Burnaby, Canada
June 22, 2018

BRITISH COLUMBIA LUNG ASSOCIATION

Financial Statements Index

Year ended March 31, 2018

	Page
Statement of Financial Position	1
Statement of Operations	2
Statement of Changes in Net Assets	3
Statement of Cash Flows	4
Notes to Financial Statements	5

	Schedules
Fundraising Expenses	1
Grants and Awards Expenses	2
Health Services Expenses	3
Operating and Administrative Expenses	4

BRITISH COLUMBIA LUNG ASSOCIATION

Statement of Financial Position

March 31, 2018, with comparative information for 2017


	2018	2017
Assets		
Current assets:		
Cash	\$ 399,728	\$ 491,142
Investments (note 3)	6,089,671	6,362,165
Accounts receivable	681,903	899,557
Prepaid expenses	20,428	18,089
	<u>7,191,730</u>	<u>7,770,953</u>
Investments (note 3)	1,518,782	1,518,782
Other assets (note 4)	29,791	28,270
Capital assets (note 5)	1,719,836	1,724,636
	<u>\$ 10,460,139</u>	<u>\$ 11,042,641</u>
Liabilities and Net Assets		
Current liabilities:		
Accounts payable and accrued liabilities	\$ 419,577	\$ 319,165
Deferred contributions (note 6)	824,404	911,571
	<u>1,243,981</u>	<u>1,230,736</u>
Net assets:		
Unrestricted	7,496,322	8,087,269
Invested in capital assets	1,719,836	1,724,636
	<u>9,216,158</u>	<u>9,811,905</u>
Commitments (note 9)		
	<u>\$ 10,460,139</u>	<u>\$ 11,042,641</u>

See accompanying notes to financial statements.

Approved on behalf of the Board:



Director and Chairperson



Director and Honorary Treasurer

BRITISH COLUMBIA LUNG ASSOCIATION

Statement of Operations

Year ended March 31, 2018, with comparative information for 2017

	2018	2017
Revenue:		
Contributions from fundraising campaigns:		
Direct Mail	\$ 1,084,088	\$ 1,173,960
Bike Trek	210,508	240,285
Climb the Wall	75,282	80,789
Golf Cards	43,187	48,657
Race and Urban Scavenger Hunt	37,592	50,864
SuperTeam	14,769	14,398
Gaming	500	-
Vehicle Donation Program	1,395	1,000
	<hr/>	<hr/>
	1,467,321	1,609,953
Government grants	2,727,903	2,699,675
Bequests and memorials	424,164	608,961
Investment income	142,159	191,581
Donations	305,760	301,185
Other	246,008	236,567
	<hr/>	<hr/>
	5,313,315	5,647,922
Expenses:		
Fundraising (schedule 1)	958,112	1,233,835
Grants and awards (schedule 2)	807,016	1,119,902
Health services (schedule 3)	3,644,016	3,516,780
Operating and administrative (schedule 4)	554,718	530,862
	<hr/>	<hr/>
	5,963,862	6,401,379
Deficiency of revenue over expenses before undernoted	(650,547)	(753,457)
Change in fair value of investments	75,053	255,918
Unrealized foreign exchange gain (loss)	(20,253)	14,564
	<hr/>	<hr/>
	54,800	270,482
Deficiency of revenue over expenses	<hr/>	<hr/>
	\$ (595,747)	\$ (482,975)

See accompanying notes to financial statements.

BRITISH COLUMBIA LUNG ASSOCIATION

Statement of Changes in Net Assets

Year ended March 31, 2018, with comparative information for 2017

	Unrestricted	Invested in capital assets	2018	2017
Balance, beginning of year	\$ 8,087,269	\$ 1,724,636	\$ 9,811,905	\$ 10,294,880
Deficiency of revenue over expenses	(534,390)	(61,357)	(595,747)	(482,975)
Purchase of capital assets	(56,557)	56,557	-	-
Balance, end of year	\$ 7,496,322	\$ 1,719,836	\$ 9,216,158	\$ 9,811,905

See accompanying notes to financial statements.

BRITISH COLUMBIA LUNG ASSOCIATION

Statement of Cash Flows

Year ended March 31, 2018, with comparative information for 2017

	2018	2017
Cash provided by (used in):		
Operating:		
Deficiency of revenue over expenses	\$ (595,747)	\$ (482,975)
Items not involving cash:		
Amortization of capital assets	60,638	51,498
Fair value change of investments	(75,053)	(255,918)
Unrealized foreign exchange loss (gain)	20,253	(14,564)
Loss on disposal of capital assets	719	-
Change in non-cash operating working capital:		
Decrease (increase) in accounts receivable	217,654	(47,714)
Increase in prepaid expenses	(2,339)	(2,422)
Increase in other assets	(1,521)	(1,573)
Increase (decrease) in accounts payable and accrued liabilities	100,412	(178,828)
Increase (decrease) in deferred contributions	(87,167)	213,769
	(362,151)	(718,727)
Investments:		
Purchase of investments	(3,864,346)	(3,989,800)
Proceeds from sale of investments	4,191,640	5,209,704
Purchase of capital assets	(56,557)	(47,425)
	270,737	1,172,479
Increase (decrease) in cash	(91,414)	453,752
Cash, beginning of year	491,142	37,390
Cash, end of year	\$ 399,728	\$ 491,142

See accompanying notes to financial statements.

BRITISH COLUMBIA LUNG ASSOCIATION

Notes to Financial Statements

Year ended March 31, 2018

1. Operations:

British Columbia Lung Association (the "Association") is incorporated under the Society Act (British Columbia). The purpose of the Association is to support medical research and education programs aimed at respiratory disease and to conduct fundraising activities to provide financial support for such programs. On March 28, 2018, the Association transitioned to the new Societies Act (British Columbia).

The Association is a registered charity under the Income Tax Act (Canada) and is exempt from Canadian federal and provincial income taxes. The Association is able to issue donation receipts for income tax purposes.

2. Significant accounting policies:

The financial statements have been prepared by management in accordance with Canadian Accounting Standards for Not-For-Profit Organizations in Part III of the Chartered Professional Accountants of Canada Handbook and include the following accounting policies:

(a) Revenue recognition:

The Association follows the deferral method of accounting for contributions which include donations and government grants. Donations are recorded when received or receivable when a realizable value can be reasonably estimated. Externally restricted contributions are initially deferred and recognized as revenue in the period in which the related expenses are incurred or the restrictions met.

Amounts received related to fundraising events to be held after the fiscal year end are deferred and recognized upon completion of the fundraising event.

Contributions of irrevocable charitable remainder trusts or life insurance policies are recorded as revenue upon receipt of funds at the net present value or cash surrender value, respectively.

Investment income is recognized as revenue when earned.

Donated gifts in-kind are recorded at fair value, when fair value can be reasonably estimated provided the goods or services would normally be required for operations. Fair value is determined to be the value of the donation at the date of the contribution. Due to the difficulty of determining the fair value, donated services of this nature are not recognized in the financial statements.

BRITISH COLUMBIA LUNG ASSOCIATION

Notes to Financial Statements (continued)

Year ended March 31, 2018

2. Significant accounting policies (continued):

(b) Capital assets:

Capital assets are stated at cost less accumulated amortization and are amortized on the declining-balance basis using the following rates:

Asset	Rate
Building	5%
Office furniture and fixtures	20%
Computer equipment	30%
Vehicles	30%
Computer software	30%

When capital assets no longer contribute to the Association's ability to provide services, its carrying amount is written down to its net realizable value.

(c) Use of estimates:

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Significant areas requiring the use of management estimates relate to the determination of useful lives of capital assets for amortization and provisions for contingencies. Actual results could differ from those estimates.

(d) Financial instruments:

Financial instruments are recorded at fair value on initial recognition. Freestanding derivative instruments that are not in a qualifying hedging relationship and equity instruments that are quoted in an active market are subsequently measured at fair value. All other financial instruments are subsequently recorded at cost or amortized cost. The Association has elected to carry guaranteed investment certificates at amortized cost and quoted shares at fair value.

Transaction costs incurred on the acquisition of financial instruments measured subsequently at fair value are expensed as incurred. All other financial instruments are adjusted by transaction costs incurred on acquisition and financing costs, which are amortized using the straight-line method.

Financial assets recorded at amortized cost are assessed for impairment on an annual basis at the end of the fiscal year if there are indicators of impairment. If there is an indicator of impairment, the Association determines if there is a significant adverse change in the expected amount or timing of future cash flows from the financial asset.

BRITISH COLUMBIA LUNG ASSOCIATION

Notes to Financial Statements (continued)

Year ended March 31, 2018

2. Significant accounting policies (continued):

(d) Financial instruments (continued):

If there is a significant adverse change in the expected cash flows, the carrying value of the financial asset is reduced to the highest of the present value of the expected cash flows, the amount that could be realized from selling the financial asset or the amount the Association expects to realize by exercising its right to any collateral. If events and circumstances reverse in a future period, an impairment loss will be reversed to the extent of the improvement, not exceeding the initial carrying value.

The Association does not hold any financial derivatives as at March 31, 2018.

3. Investments:

	2018	2017
Guaranteed investment certificates, measured at amortized cost	\$ 5,225,484	\$ 5,554,022
Quoted shares, measured at fair value	2,382,969	2,326,925
	<u>\$ 7,608,453</u>	<u>\$ 7,880,947</u>

The Guaranteed investment certificates have an effective interest rate of 1.05% to 2.20% (2017 - 1.40 % to 2.20%) with maturities of 2018 to 2020.

The total investments balance is classified as follows on the statement of financial position:

	2018	2017
Current	\$ 6,089,671	\$ 6,362,165
Long-term	1,518,782	1,518,782
	<u>\$ 7,608,453</u>	<u>\$ 7,880,947</u>

4. Other assets:

The Association has been named the irrevocable beneficiary of one (2017 - one) life insurance policy with coverage totaling \$52,449 (2017 - \$52,449). At March 31, 2018, the insurance policy has a cash surrender value, representing fair value, totaling \$29,791 (2017 - \$28,270), which is recorded as an asset. In the event that the donor discontinues paying the premiums, the Association will receive proceeds equal to the cash surrender value. Upon the death of the donor, the total coverage will be payable to the Association.

BRITISH COLUMBIA LUNG ASSOCIATION

Notes to Financial Statements (continued)

Year ended March 31, 2018

5. Capital assets:

2018	Cost	Accumulated depreciation	Net book value
Land	\$ 987,043	\$ -	\$ 987,043
Building	2,148,191	1,503,988	644,203
Office furniture and fixtures	524,465	508,226	16,239
Computer equipment	304,471	278,166	26,305
Vehicles	99,562	61,514	38,048
Computer software	49,135	41,137	7,998
	\$ 4,112,867	\$ 2,393,031	\$ 1,719,836

2017	Cost	Accumulated depreciation	Net book value
Land	\$ 987,043	\$ -	\$ 987,043
Building	2,138,948	1,470,265	668,683
Office furniture and fixtures	523,260	504,407	18,853
Computer equipment	301,976	267,789	34,187
Vehicles	71,059	66,615	4,444
Computer software	49,135	37,709	11,426
	\$ 4,071,421	\$ 2,346,785	\$ 1,724,636

6. Deferred contributions:

Changes in deferred contributions are as follows:

	2018	2017
Balance, beginning of year	\$ 911,571	\$ 697,802
Contributions received	2,945,785	2,922,409
Amount recognized as revenue	(3,032,952)	(2,708,640)
Balance, end of year	\$ 824,404	\$ 911,571

BRITISH COLUMBIA LUNG ASSOCIATION

Notes to Financial Statements (continued)

Year ended March 31, 2018

7. Pension plan:

The Association provides a defined contribution pension plan to its employees which vests after two years of service. The Association is required to pay a contribution ranging from 5% to 10% of the employee's gross pay. For the year ended March 31, 2018, the Association contributed \$96,801 (2017 - \$101,192) in pension plan payments for its employees. This amount is included in expenses.

8. Lung Foundation of British Columbia:

The Association is related to the Lung Foundation of British Columbia (the "Foundation") as all of the directors of the Foundation are also directors of the Association. The Foundation is a registered charity formed to provide funds to support research and studies into the prevention and control of lung and related diseases.

The net assets and results from operations of the Foundation have not been included in these financial statements. A financial summary of the Foundation as at and for its year ended March 31, 2018 is as follows:

	2018	2017
Financial Position:		
Total assets	\$ 830,497	\$ 848,179
Total liabilities	-	6,250
Total net assets	\$ 830,497	\$ 841,929
Results of Operations:		
Total revenue	\$ 17,968	\$ 41,265
Total expenses	(29,400)	(32,018)
	\$ (11,432)	\$ 9,247
Cash Flows:		
Operating activities	\$ (19,065)	\$ (6,906)
Investing activities	10,684	35,000

BRITISH COLUMBIA LUNG ASSOCIATION

Notes to Financial Statements (continued)

Year ended March 31, 2018

9. Commitments:

The Association is committed to expenses for grants, awards and health services. The Association is also committed to payments under an operating lease for a vehicle. The minimum annual payments under the funding and operating lease commitments are as follows:

2019	\$	206,250
2020		31,250
	\$	237,500

10. Financial risks and concentration of credit risk:

(a) Liquidity risk:

Liquidity risk is the risk that the Association will be unable to fulfill its obligations on a timely basis or at a reasonable cost. The Association manages its liquidity risk by monitoring its operating requirements. The Association prepares budget and cash forecasts to ensure it has sufficient funds to fulfill its obligations.

(b) Credit risk:

Credit risk refers to the risk that a counterparty may default on its contractual obligations resulting in a financial loss. The Association is exposed to credit risk with respect to the accounts receivable. The Association assesses, on a continuous basis, accounts receivable and provides for any amounts that are not collectible in the allowance for doubtful accounts.

(c) Interest rate risk:

The Association is exposed to fair value risk on its fixed interest rate financial instruments. Further details about the fixed rate investments are included in note 3.

11. Trust funds

Certain assets have been conveyed or assigned to the Association to be administered as directed by agreement. The Association holds these assets for the benefit of, and stands in a fiduciary relationship to, the beneficiaries. The Better Pharmacare Coalition and STOP TB funds of \$38,797 (2017 - \$28,034) and \$5,469 (2017 - \$5,778), respectively, which are administered by the Association, have not been included within the Association's accounts.

12. Employee remuneration

For the fiscal year ending March 31, 2018, the British Columbia Lung Association paid total remuneration of \$721,645 (2017 - \$780,058) to six employees, each of whom received total annual remuneration of \$75,000 or greater. No remuneration was paid to directors.

BRITISH COLUMBIA LUNG ASSOCIATION

Fundraising expenses

Schedule 1

Year ended March 31, 2018, with comparative information for 2017

	2018	2017
Administrative:		
Credit card and online fees	\$ 8,569	\$ 11,343
Data processing and mechanical inserting	43,443	43,705
Education and training	273	1,615
Licenses and memberships	420	1,085
Publicity	17,367	36,021
Programs	76,813	94,549
Salaries and employee benefits	485,849	502,435
Telephone	4,158	7,038
Travel and meetings	19,417	20,718
Volunteers	2,784	4,469
	<u>659,093</u>	<u>722,978</u>
Materials	113,099	156,615
Postage	185,920	354,242
	<u>\$ 958,112</u>	<u>\$ 1,233,835</u>

BRITISH COLUMBIA LUNG ASSOCIATION

Grants and Awards expenses

Schedule 2

Year ended March 31, 2018, with comparative information for 2017

	2018	2017
Fellowships:		
Respiratory Medicine:		
Dr. S. Grzybowski Memorial	\$ 25,000	\$ 25,000
Dr. W. Thurlbeck Memorial	25,000	25,000
Pulmonary Radiology - Dr. R. Miller Memorial	6,250	25,000
Pulmonary Pathology - Dr. K. Pump Memorial	25,000	25,000
Rehabilitation Medicine	25,000	18,750
Transitional TB Research	-	50,000
	106,250	168,750
Ongoing grants:		
UBC Continuing Professional Dev. & Knowledge Translation	18,000	18,000
Nursing Bursaries - Community Colleges	9,000	7,000
Canadian Lung Association - Research	76,679	74,747
Canadian Lung Association - Annual	125,742	125,055
Respiratory Technology Bursary - TRU	3,000	3,000
International Union Against TB and Lung Disease	8,060	7,113
Hidalgo Lung Association Project	2,497	-
Helen H. Findlay Nursing Bursary - BCIT	1,000	1,000
Justice Institute of BC - First Responder Award	1,000	1,000
Canadian Respiratory Network Investigator Award	-	50,000
UBC Academic Enhancement Fund - Respiratory Division	-	200,000
	244,978	486,915
Community service projects:		
Healthy Living Alliance	10,000	10,000
Direct Patient Support	8,100	8,800
Community respiratory programs	15,000	16,000
	33,100	34,800
Project and equipment grants - Approved June 2017:		
Dr. Najib Ayas – Assessing the impact of maternal sleep apnea on fetal and placental health	12,500	-
Dr. Pat Camp – A community-based research project to improve lung health in remote and rural first nations communities in BC	12,500	-
Dr. Harvey Coxson – Development and validation of novel non-invasive imaging tools to enhance our understanding of airways in asthma	12,500	-
Dr. Nancy Ford – In vivo and ex vivo assessment of COPD progression in preclinical models	12,500	-
Dr. Jennifer Gardy – Genomic epidemiology of non-TB mycobacteria infection in Cystic Fibrosis	12,500	-
Dr. Jordan Guenette – A double-blind placebo-controlled crossover study to assess the effect of bronchodilation on CF patients	12,500	-
Dr. Janice Leung – The role of gut-lung axis in the aging HIV lung	12,500	-
Dr. Manish Sadarangani – Molecular epidemiology of streptococcus pneumoniae in children and vaccine design	12,500	-
Dr. Andrew Sandford – Genetic variants of TSLP in asthma	12,500	-
Dr. Scott Tebbutt – Novel diagnosis of Western Red Cedar Asthma	12,500	-
Dr. Lu Wang – Cytoskeletal stiffness of airway smooth muscle – A new target for asthma strategy	12,500	-
	137,500	-
Carried forward	521,828	690,465

BRITISH COLUMBIA LUNG ASSOCIATION

Grants and Awards expenses

Schedule 2
(continued)

Year ended March 31, 2018, with comparative information for 2017

	2018	2017
Brought forward	521,828	690,465
Project and equipment grants - Approved June 2016:		
Dr. Lindsay Eltis - Inhibitors of cholesterol catabolism in mycobacterium tuberculosis	20,000	10,000
Dr. Sarah Henderson - Distance to oil and gas drilling and its association with acute respiratory and cardiovascular health outcomes in northeastern BC from 1996-2015	25,000	12,500
Dr. Jeremy Hirota - Identification and functional characterization of a novel antiviral sensor relevant in chronic airway diseases - ATP Binding Cassette Transporter F1	25,000	12,500
Dr. Pascal Lavoie - Genetics of neonatal chronic lung disease: A replication study	25,000	12,500
Dr. Honglin Luo - Development of a novel coxsackievirus B3-based oncolytic virus for lung cancer therapy	25,000	12,500
Dr. Bradley Quon - Discovery of blood protein biomarkers to monitor treatment responses during CF pulmonary exacerbations	22,500	11,250
Dr. Fernando Studart Leitao - Serum immunoglobulins and risk of exacerbations in COPD	20,000	10,000
	162,500	81,250
Project and equipment grants - Approved June 2015:		
Dr. Yossef Av-Gay - Intracellular growth of mycobacterium tuberculosis: prospects for drug discovery	7,688	23,062
Dr. Delbert Dorscheid - Conjugated Linoleic Acid ("CLA"): A Novel and natural anti-viral and anti-inflammatory molecule in asthma	12,500	25,000
Dr. David Granville Extracellular Granzyme B and pulmonary epithelial barrier disruption	12,500	25,000
Dr. Sarah Henderson - The respiratory and cardiovascular risks associated with sub-daily exposure to forest fire smoke	12,500	25,000
Dr. Zakaria Hmama - Attenuated proapoptotic BCG strains as novel TB vaccines	12,500	25,000
Dr. Janice Leung - Accelerated aging and oxidative stress: Mechanisms of lung disease in HIV	12,500	25,000
Dr. Ma'En Obeidat - Integrative genomics approach to unravel the molecular mechanisms underlying lung function measures and lung cancer	12,500	25,000
Dr. Christopher Ryerson - Researching frailty, sarcopenia and healthcare costs in fibrotic interstitial lung disease	12,500	25,000
Dr. Andrew Sandford Genetic determinants of obstructive sleep apnea	12,500	25,000
Dr. William Sheel - The aging lung: Sex differences in the sensation of breathlessness during exercise	12,500	25,000
	120,188	248,062
Carried forward	804,516	1,019,777

BRITISH COLUMBIA LUNG ASSOCIATION

Grants and Awards expenses

Schedule 2
(continued)

Year ended March 31, 2018, with comparative information for 2017

	2018	2017
Brought forward	804,516	1,019,777
Project and equipment grants - Approved June 2014:		
Dr. Christopher Carlsten - A novel approach to characterizing the human airway responses to complex environmental exposures	-	12,500
Dr. Vincent Duronio - Aberrant p53-mediated signaling in the pathogenesis of idiopathic pulmonary fibrosis	-	12,500
Dr. Lindsay Eltis - Inhibitors of cholesterol catabolism in <i>mycobacterium tuberculosis</i>	-	12,500
Dr. Jeremy Hirota - The role of uric acid in airway health and disease	-	12,500
Dr. Bradley Quon - Identification of novel blood biomarkers to predict pulmonary exacerbations in cystic fibrosis	-	12,500
Dr. Santiago Ramon-Garcia - Repurposing veterinary anti-parasitic drugs to treat tuberculosis	-	12,500
Dr. Nico Marr - Immunological determinants of severe respiratory syncytial virus infection in early life	-	12,500
	-	87,500
Other grants:		
Miscellaneous grants	2,500	12,625
	\$ 807,016	\$ 1,119,902

BRITISH COLUMBIA LUNG ASSOCIATION

Health services expense

Schedule 3

Year ended March 31, 2018, with comparative information for 2017

	2018	2017
Data processing	\$ 13,093	\$ 11,028
Education and training	1,482	2,111
Health education material	1,222	2,255
Licenses and memberships	667	782
Medical equipment	1,090	1,321
Online and Educational Engagement	1,575	6,281
Postage	59,125	20,219
Printing and supplies	32,891	12,037
Programs	2,846,137	2,805,348
Publicity	13,118	4,685
Salaries and employee benefits	603,134	584,290
Telephone	4,269	7,375
Travel and meetings	47,423	29,588
Volunteers	1,513	1,277
"Your Health" magazine	17,277	28,183
	<u>\$ 3,644,016</u>	<u>\$ 3,516,780</u>

BRITISH COLUMBIA LUNG ASSOCIATION

Operating and administrative expenses

Schedule 4

Year ended March 31, 2018, with comparative information for 2017

	2018	2017
Amortization	\$ 60,638	\$ 51,498
Audit and legal	42,498	24,862
Building maintenance	33,556	36,164
Data processing	10,745	15,482
Directors' meetings and travel	39,581	45,356
Education and training	134	1,113
Equipment maintenance	7,238	2,240
General insurance	20,658	19,960
Interest and bank charges	25,495	24,692
Janitorial services	7,333	7,521
Licenses and memberships	876	1,091
Light, heat and water	18,997	20,121
Postage	980	1,171
Salaries and employee benefits	256,834	249,888
Stationery and office supplies	5,733	4,632
Telephone	6,179	7,914
Travel and meetings - staff	17,243	17,157
	<u>\$ 554,718</u>	<u>\$ 530,862</u>